{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:26:35Z","timestamp":1790346395262,"version":"4.1.0"},"reference-count":23,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Nivolumab is a standard-of-care adjuvant therapy for patients with muscle-invasive urothelial carcinoma (MIUC) at high risk for recurrence after radical resection. However, a better understanding of its use and clinical effectiveness in general patient populations is needed.<\/jats:p><\/jats:sec>Objective<\/jats:title>To examine treatment patterns and clinical outcomes for patients with MIUC treated with adjuvant nivolumab in a community setting.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This nationwide retrospective medical record review cohort study included patients with clinical stage II to IIIB MIUC who initiated adjuvant nivolumab between September 1, 2021, and November 30, 2022, with at least 6 months follow-up (unless deceased in &amp;lt;6 months). Managing physicians from the Cardinal Health Oncology Provider Extended Network abstracted patient data from electronic records.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Diagnosis of MIUC and receipt of adjuvant nivolumab.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Disease-free survival (DFS) and overall survival (OS) were estimated using Kaplan-Meier methods.<\/jats:p><\/jats:sec>Results<\/jats:title>Data from 253 patients were included in this study, with median (IQR) follow-up from adjuvant nivolumab initiation of 12.8 (9.6-15.4) months. The median (IQR) age at MIUC diagnosis was 67.8 (61.5-72.4) years, and most patients were male (169 patients [66.8%]). Overall, 141 patients (55.7%) had received neoadjuvant chemotherapy (NAC). During adjuvant nivolumab, 52 patients (20.6%) experienced an adverse event (AE). At last follow-up, the median (IQR) duration of adjuvant nivolumab was 11.2 (8.4-12.0) months, and 220 patients (87.0%) had discontinued treatment. Discontinuation was primarily due to completion of scheduled therapy duration (163 of 220 patients [74.1%]), while 10 of 220 patients (4.5%) discontinued due to AEs. Median DFS and OS were not reached, and estimates at 12 months after initiation were 86.3% (95% CI, 81.0%-90.2%) for DFS and 90.8% (95% CI, 86.0%-94.0%) for OS. Outcomes were similar in patients who did not receive NAC. At last follow-up, 226 patients (89.3%) were alive, of whom 209 (92.5%) were disease-free.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This retrospective medical record review cohort study of patients with MIUC found clinical outcomes consistent with those observed in the CheckMate 274 trial. These results support the use of adjuvant nivolumab for patient populations in the community, including patients who did not receive NAC. Further research with extended follow-up is needed to elucidate long-term clinical outcomes of adjuvant nivolumab.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.14427","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T15:00:26Z","timestamp":1749481226000},"page":"e2514427","source":"Crossref","is-referenced-by-count":5,"title":["Clinical Outcomes in Patients With Muscle-Invasive Urothelial Carcinoma Treated With Nivolumab"],"prefix":"10.1001","volume":"8","author":[{"given":"Regina","family":"Barrag\u00e1n-Carrillo","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedyeh","family":"Ebrahimi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William S.","family":"John","sequence":"additional","affiliation":[{"name":"Real World Evidence & Insights, Cardinal Health, Dublin, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Lucht","sequence":"additional","affiliation":[{"name":"Real World Evidence & Insights, Cardinal Health, Dublin, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taavy A.","family":"Miller","sequence":"additional","affiliation":[{"name":"Real World Evidence & Insights, Cardinal Health, Dublin, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prathamesh","family":"Pathak","sequence":"additional","affiliation":[{"name":"Real World Evidence & Insights, Cardinal Health, Dublin, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Bland","sequence":"additional","affiliation":[{"name":"Real World Evidence & Insights, Cardinal Health, Dublin, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Gordon","sequence":"additional","affiliation":[{"name":"Real World Evidence & Insights, Cardinal Health, Dublin, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JaLyna","family":"Laney","sequence":"additional","affiliation":[{"name":"Real World Evidence & Insights, Cardinal Health, Dublin, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Klink","sequence":"additional","affiliation":[{"name":"Real World Evidence & Insights, Cardinal Health, Dublin, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Feinberg","sequence":"additional","affiliation":[{"name":"Real World Evidence & Insights, Cardinal Health, Dublin, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha","family":"Singh","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Alonso","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miraj Y.","family":"Patel","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Rosenblatt","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Yin","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Chehrazi-Raffle","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,6,9]]},"reference":[{"issue":"2","key":"zoi250475r3","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.eururo.2023.03.029","article-title":"Epidemiology of bladder cancer in 2023: a systematic review of risk factors.","volume":"84","author":"Jubber","year":"2023","journal-title":"Eur Urol"},{"issue":"1","key":"zoi250475r4","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/S1470-2045(14)71160-X","article-title":"Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.","volume":"16","author":"Sternberg","year":"2015","journal-title":"Lancet Oncol"},{"issue":"6","key":"zoi250475r5","doi-asserted-by":"publisher","first-page":"S237","DOI":"10.5489\/cuaj.1205","article-title":"Surveillance strategies after definitive therapy of invasive bladder cancer.","volume":"3","author":"Cagiannos","year":"2009","journal-title":"Can Urol Assoc J"},{"issue":"35","key":"zoi250475r6","doi-asserted-by":"publisher","first-page":"5519","DOI":"10.1200\/JCO.2006.08.5431","article-title":"Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessments.","volume":"24","author":"Parekh","year":"2006","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi250475r7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.eururo.2021.09.028","article-title":"Adjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and meta-analysis of individual participant data from randomised controlled trials.","volume":"81","author":"Advanced Bladder Cancer (ABC) Meta-analysis Collaborators Group","year":"2022","journal-title":"Eur Urol"},{"issue":"22","key":"zoi250475r8","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma.","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi250475r9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1200\/JCO.24.00340","article-title":"Adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma: expanded efficacy from CheckMate 274.","volume":"43","author":"Galsky","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi250475r10","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/cncr.24701","article-title":"Racial differences in treatment and outcomes among patients with early stage bladder cancer.","volume":"116","author":"Hollenbeck","year":"2010","journal-title":"Cancer"},{"issue":"1","key":"zoi250475r11","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12894-023-01293-8","article-title":"Racial disparities in conditional survival of patients with bladder cancer: a population-based study.","volume":"23","author":"Liu","year":"2023","journal-title":"BMC Urol"},{"issue":"1","key":"zoi250475r12","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12967-020-02308-w","article-title":"Ethnicity and survival in bladder cancer: a population-based study based on the SEER database.","volume":"18","author":"Fang","year":"2020","journal-title":"J Transl Med"},{"issue":"1","key":"zoi250475r13","doi-asserted-by":"publisher","first-page":"76.e15","DOI":"10.1016\/j.urolonc.2020.07.011","article-title":"\u201cReal-world\u201d outcomes and prognostic indicators among patients with high-risk muscle-invasive urothelial carcinoma.","volume":"39","author":"Drakaki","year":"2021","journal-title":"Urol Oncol"},{"key":"zoi250475r14","doi-asserted-by":"publisher","first-page":"S1560","DOI":"10.1016\/j.annonc.2023.10.354","article-title":"Clinical effectiveness of tislelizumab combined with gemcitabine\/cisplatin (GC) versus GC as adjuvant therapy in high-risk muscle-invasive urothelial carcinoma (MIUC): a real-world study.","volume":"34","author":"Tan","year":"2023","journal-title":"Ann Oncol"},{"key":"zoi250475r15","doi-asserted-by":"publisher","first-page":"808","DOI":"10.3389\/fonc.2020.00808","article-title":"Checkpoint inhibition for metastatic urothelial carcinoma after chemotherapy: real-world clinical impressions and comparative review of the literature.","volume":"10","author":"Fuhrmann","year":"2020","journal-title":"Front Oncol"},{"issue":"3","key":"zoi250475r16","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1097\/JU.0000000000001412","article-title":"Comparative effectiveness of immune checkpoint inhibitors in patients with platinum refractory advanced urothelial carcinoma.","volume":"205","author":"Swami","year":"2021","journal-title":"J Urol"},{"issue":"6","key":"zoi250475r17","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s00262-024-03682-w","article-title":"Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study.","volume":"73","author":"Massari","year":"2024","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"zoi250475r18","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.clgc.2020.01.004","article-title":"Programmed death 1 and programmed death ligand 1 inhibitors in advanced and recurrent urothelial carcinoma: meta-analysis of single-agent studies.","volume":"18","author":"Tafuri","year":"2020","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"zoi250475r19","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","article-title":"Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.","volume":"22","author":"Bellmunt","year":"2021","journal-title":"Lancet Oncol"},{"issue":"19","key":"zoi250475r20","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer.","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi250475r21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa2401726","article-title":"Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma.","volume":"392","author":"Apolo","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi250475r22","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70661","article-title":"Clinical effectiveness of tislelizumab with gemcitabine\/cisplatin versus gemcitabine\/cisplatin alone as adjuvant therapy for high-risk muscle-invasive urothelial carcinoma: a real-world study.","volume":"14","author":"Wang","year":"2025","journal-title":"Cancer Med"},{"issue":"1","key":"zoi250475r23","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s12885-024-11919-1","article-title":"The efficacy and safety of tislelizumab combined with gemcitabine plus cisplatin in the treatment of postoperative patients with muscle-invasive upper tract urothelial carcinoma.","volume":"24","author":"Zhang","year":"2024","journal-title":"BMC Cancer"},{"key":"zoi250475r1","unstructured":"National Cancer Institute Surveillance and End Results Program. Cancer stat facts: bladder cancer. 2024. Accessed May 5, 2025. https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html"},{"key":"zoi250475r2","unstructured":"American Cancer Society. Cancer facts & figures 2023. Accessed May 5, 2025. https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/2023-cancer-facts-figures.html"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2835112\/barragncarrillo_2025_oi_250475_1748641539.67886.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T15:00:29Z","timestamp":1749481229000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2835112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,9]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.14427","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,9]]}}}